DnaJ heat shock protein family (Hsp40) member C19 pseudogene 9Genealiases: []
Q-omics provides the consensus-scored DNAJC19P9 profile across patient tissues and cancer cell-line models. DNAJC19P9 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, DNAJC19P9 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, DNAJC19P9 RNA expression shows 10,340 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight CESC, COAD, and KICH as cancer lineages where DNAJC19P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC19P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC19P9 survival associations across molecular data types. DNAJC19P9 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC19P9 RNA expression–survival associations across cancer types. High DNAJC19P9 expression shows unfavorable associations in KICH and LGG, but favorable associations in CESC, LUSC, BLCA and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for DNAJC19P9 RNA expression.
This table summarizes DNAJC19P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for DNAJC19P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC19P9 shows lower tumor expression in KIRC and KIRP and higher tumor expression in COAD, HNSC, LUSC and BRCA. The COAD box plot shows higher DNAJC19P9 RNA expression in tumor versus normal tissue (log2 FC = +1.105, t-test p < 0.001).
This table shows molecular features associated with DNAJC19P9 in patient tissues and cancer cell lines. In patient samples, DNAJC19P9 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
